Drug Profile
Research programme: small molecule therapeutics - AbbVie
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator X-Chem
- Developer AbbVie; X-Chem
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Immunological disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in USA
- 28 Aug 2020 No recent reports of development identified for research development in Immunological-disorders in USA
- 13 Mar 2018 AbbVie exercises options to license two discovery programmes for Cancer and Immunological disorders from X-Chem